Prothrombotic effects of fibronectin isoforms containing the EDA domain

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 2, 2008, Pages 296-301

  Chauhan, Anil K ^a   Kisucka, Janka ^a   Cozzi, Maria R ^b   Walsh, Meghan T ^a   Moretti, Federico A ^c   Battiston, Monica ^b   Mazzucato, Mario ^b   De Marco, Luigi ^b   Baralle, Francisco E ^c   Wagner, Denisa D ^a   Muro, Andrés F ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

Arterial and venous injury; Arterial thrombosis; Fibronectin splice variants isoforms; Intravital microscopy; Plasma fibronectin; Thromboembolism

Indexed keywords

FIBRONECTIN; PROTEIN EXTRA DOMAIN A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLEEDING TIME; BLOOD CLOTTING TIME; CONTROLLED STUDY; LUNG EMBOLISM; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHEAR RATE; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

ANIMALS; DISEASE MODELS, ANIMAL; FIBRONECTINS; MICE; MICE, KNOCKOUT; PLATELET ACTIVATION; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; PULMONARY EMBOLISM;

EID: 38549167658     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.149146     Document Type: Article

References (36)

1. Ni H, Denis CV, Subbarao S, Degen JL, Sato TN, Hynes RO, Wagner DD. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest. 2000;106:385-392.
2. Cho J, Mosher DF. Enhancement of thrombogenesis by plasma fibronectin cross-linked to fibrin and assembled in platelet thrombi. Blood. 2006;107:3555-3563.
3. Matuskova J, Chauhan AK, Cambien B, Astrof S, Dole VS, Piffath CL, Hynes RO, Wagner DD. Decreased plasma fibronectin leads to delayed thrombus growth in injured arterioles. Arterioscler Thromb Vasc Biol. 2006;26:1391-1396.
4. Ni H, Yuen PS, Papalia JM, Trevithick JE, Sakai T, Fassler R, Hynes RO, Wagner DD. Plasma fibronectin promotes thrombus growth and stability in injured arterioles. Proc Natl Acad Sci U S A. 2003;100:2415-2419.
5. Hynes RO. Fibronectins. New York: Springer-Verlag; 1990.
6. Mosher DF. Fibronectin. New York: Academic Press; 1989.
7. Kornblihtt AR, Umezawa K, Vibe-Pedersen K, Baralle FE. Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene. Embo J. 1985;4:1755-1759.
8. Tamkun JW, Schwarzbauer JE, Hynes RO. A single rat fibronectin gene generates three different mRNAs by alternative splicing of a complex exon. Proc Natl Acad Sci U S A. 1984;81:5140-5144.
9. Zardi L, Carnemolla B, Siri A, Petersen TE, Paolella G, Sebastio G, Baralle FE. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. Embo J. 1987;6:2337-2342.
10. Pankov R, Yamada KM. Fibronectin at a glance. J Cell Sci. 2002;115:3861-3863.
11. Paul JI, Schwarzbauer JE, Tamkun JW, Hynes RO. Cell-type-specific fibronectin subunits generated by alternative splicing. J Biol Chem. 1986;261:12258-12265.
12. Castellanos M, Leira R, Serena J, Blanco M, Pedraza S, Castillo J, Davalos A. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke. 2004;35:1671-1676.
13. Kanters SD, Banga JD, Algra A, Frijns RC, Beutler JJ, Fijnheer R. Plasma levels of cellular fibronectin in diabetes. Diabetes Care. 2001;24:323-327.
14. Peters JH, Maunder RJ, Woolf AD, Cochrane CG, Ginsberg MH. Elevated plasma levels of ED1+ ("cellular") fibronectin in patients with vascular injury. J Lab Clin Med. 1989;113:586-597.
15. Tan MH, Sun Z, Opitz SL, Schmidt TE, Peters JH, George EL. Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis. Blood. 2004;104:11-18.
16. van der Plas RM, Schiphorst ME, Huizinga EG, Hene RJ, Verdonck LF, Sixma JJ, Fijnheer R. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood. 1999;93:3798-3802.
17. Vincent PA, Rebres RA, Lewis EP, Hurst Vt, Saba TM. Release of ED1 fibronectin from matrix of perfused lungs after vascular injury is independent of protein synthesis. Am J Physiol. 1993;265:L485-L492.
18. Muro AF, Chauhan AK, Gajovic S, Iaconcig A, Porro F, Stanta G, Baralle FE. Regulated splicing of the fibronectin EDA exon is essential for proper skin wound healing and normal lifespan. J Cell Biol. 2003;162:149-160.
19. Chauhan AK, Motto DG, Lamb CB, Bergmeier W, Dockal M, Plaimauer B, Scheiflinger F, Ginsburg D, Wagner DD. Systemic antithrombotic effects of ADAMTS13. J Exp Med. 2006;203:767-776.
20. Yang J, Wu J, Kowalska MA, Dalvi A, Prevost N, O'Brien PJ, Manning D, Poncz M, Lucki I, Blendy JA, Brass LF. Loss of signaling through the G protein, Gz, results in abnormal platelet activation and altered responses to psychoactive drugs. Proc Natl Acad Sci U S A. 2000;97:9984-9989.
21. Odawara A, Kikkawa K, Katoh M, Toryu H, Shimazaki T, Sasaki Y. Inhibitory effects of TA-993, a new 1,5-benzothiazepine derivative, on platelet aggregation. Circ Res. 1996;78:643-649.
22. Mazzucato M, Spessotto P, Masotti A, De Appollonia L, Cozzi MR, Yoshioka A, Perris R, Colombatti A, De Marco L. Identification of domains responsible for von Willebrand factor type VI collagen interaction mediating platelet adhesion under high flow. J Biol Chem. 1999;274:3033-3041.
23. Chauhan AK, Kisucka J, Lamb CB, Bergmeier W, Wagner DD. von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins. Blood. 2007;109:2424-2429.
24. Moretti FA, Chauhan AK, Iaconcig A, Porro F, Baralle FE, Muro AF. A major fraction of fibronectin present in the extracellular matrix of tissues is plasma-derived. J Biol Chem. 2007;282:28057-28062.
25. Sakai T, Johnson KJ, Murozono M, Sakai K, Magnuson MA, Wieloch T, Cronberg T, Isshiki A, Erickson HP, Fassler R. Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. Nat Med. 2001;7:324-330.
26. Mosher DF. Cross-linking of cold-insoluble globulin by fibrin-stabilizing factor. J Biol Chem. 1975;250:6614-6621.
27. Wilson CL, Schwarzbauer JE. The alternatively spliced V region contributes to the differential incorporation of plasma and cellular fibronectins into fibrin clots. J Cell Biol. 1992;119:923-933.
28. Chauhan AK, Iaconcig A, Baralle FE, Muro AF. Alternative splicing of fibronectin: a mouse model demonstrates the identity of in vitro and in vivo systems and the processing autonomy of regulated exons in adult mice. Gene. 2004;324:55-63.
29. ffrench-Constant C. Alternative splicing of fibronectin-many different proteins but few different functions. Exp Cell Res. 1995;221:261-271.
30. Kornblihtt AR, Pesce CG, Alonso CR, Cramer P, Srebrow A, Werbajh S, Muro AF. The fibronectin gene as a model for splicing and transcription studies. Faseb J. 1996;10:248-257.
31. Liao YF, Gotwals PJ, Koteliansky VE, Sheppard D, Van De Water L. The EIIIA segment of fibronectin is a ligand for integrins alpha 9beta 1 and alpha 4beta 1 providing a novel mechanism for regulating cell adhesion by alternative splicing. J Biol Chem. 2002;11:11.
32. Manabe R, Ohe N, Maeda T, Fukuda T, Sekiguchi K. Modulation of cell-adhesive activity of fibronectin by the alternatively spliced EDA segment. J Cell Biol. 1997;139:295-307.
33. Zhong C, Chrzanowska-Wodnicka M, Brown J, Shaub A, Belkin AM, Burridge K. Rho-mediated contractility exposes a cryptic site in fibronectin and induces fibronectin matrix assembly. J Cell Biol. 1998;141:539-551.
34. Johnson KJ, Sage H, Briscoe G, Erickson HP. The compact conformation of fibronectin is determined by intramolecular ionic interactions. J Biol Chem. 1999;274:15473-15479.
35. Niimi T, Osawa M, Yamaji N, Yasunaga K, Sakashita H, Mase T, Tanaka A, Fujita S. NMR structure of human fibronectin EDA. J Biomol NMR. 2001;21:281-284.
36. Cho J, Mosher DF. Role of fibronectin assembly in platelet thrombus formation. J Thromb Haemost. 2006;4:1461-1469.